Brean Capital Maintains Buy On TG Therapeutics On The Heels Of SPA Agreement

In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $19 price target, following special protocol assessment (SPA) agreement with the FDA for the company’s first Phase 3 trial for TG-1101 plus ibrutinib for CLL patients with high-risk cytogenetics, achieving a priority in developing this combination therapy.

Aschoff noted, “We note TG management’s continued solid execution regarding both of its drug programs, aided by its alliance with US Oncology for Phase 2 and now Phase 3. More details about the SPA will be announced at the launch of the Phase 3 trial by YE14. We note that Dr. Sharman, the lead investigator in the Phase 2 trial of TG-1101 plus ibrutinib will also lead the Phase 3 trial, which speaks to the impressive efficacy and safety seen so far with this combination. The Phase 2 trial of TG-1101 plus ibrutinib is now fully enrolled, with efficacy and safety data from more than 30 Phase 2 CLL patients to be available at the ASH conference in December.”

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 17.4% and a 58.5% success rate. Aschoff has a 6.6% average return when recommending TGTX, and is ranked #165 out of 3274 analysts.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts